Treatment options in metastatic renal carcinoma: An embarrassment of riches

被引:51
作者
Vogelzang, NJ [1 ]
机构
[1] Univ Nevada, Sch Med, Las Vegas, NV 89154 USA
[2] Nevada Canc Inst, Las Vegas, NV USA
关键词
D O I
10.1200/JCO.2005.03.7234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1 / 3
页数:3
相关论文
共 14 条
[11]   Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma [J].
Rini, BI ;
Small, EJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1028-1043
[12]  
Schama Simon., 1988, EMBARRASSMENT RICHES
[13]  
Spigel DR, 2005, J CLIN ONCOL, V23, p387S
[14]   A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].
Yang, JC ;
Haworth, L ;
Sherry, RM ;
Hwu, P ;
Schwartzentruber, DJ ;
Topalian, SL ;
Steinberg, SM ;
Chen, HX ;
Rosenberg, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434